Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
so mature Joey
your sophomoric reply exemplifies your true character “Warp”
keep buy those worthless TOMDF shares - Gerald loves you for it
14 followers - says it all
SMH - nuff said….!
MOO ignorant
we’ll spoken
unfortunately it was wasted words - falling on deaf ears…
TOMDF shills & touts come with ulterior motives - lolzzz
DB has brains - connections - and deep pockets…!
$MONI
nice post…
MONI going to surprise
~~~ BIGLEY ~~~
nuff sad
printing $0.0005 pps
that’s all the dodgie deflection and in-deference you need to know
3-Bil. OS just around the bend sonny…!
MOO shite
that guy is a TOMDF shill and dolt
he’s got ZERO bragging rights in MONI whatsoever
expecting to be pleasantly surprised - soon enough
MONI baby….!
bit of advice Joey
hang it up and go back to your TOMDF
this table here is for serious players
nuff said
BAF MONI
you got it all twisted swordman
nothing in my post said anything about "not liking the participants"
nothing in my post said anything about "TolloVID is not shown as a participant"
nothing said in my post said anything about "expecting a bottle of TolloVID to be shown as a Dr."
nothing in my post said anything about not "finding some solace in patients getting well"
you need to learn to not only read, but interpret what is written
your response commentary is sad - as usual...
medical food sales - really - no EAU - Oy Vey...!
SMH - nuff said
MOO failure
Todos and Dr Arad nowhere to be found in the LH Covid line-up
ghee, I wonder what that is....?
could it be the TOMDF horsies have all run astray...?
Giddy-up my pearly right cheek arse...!
just another conference...
ask yourself this - how many shares were in the float at the time of this World Anti-Virus conference...?
here we are 1-year later with 3-BILLION OS shares
SMH - sad but true
MOO pathetic
signs of desperation
the Stanford "Financial Engineer" will ALWAYS prosper on the gullible, novice, unsuspecting & underwater TOMDF shareholders - his income depends on the never ending issuance of more & more toxic death spiral convertible shares, aka serial dilution
that's what Gerald does - he leaches off the public markets - and leaves his desecrated mess for others to clean-up
oh that look on Jon Najarian's face says it all...!
SMH - sad but true...!
AJMHO
what??? another 75-Mil more toxic death spiral diluted shares added to the already bloated serial float
heading to 3-Bil. - yes that right folks 3-Bil. spelled "BILLION" shares
soon to be in the toxic death spiral convertible float that is - good job Gerald you Financial Engineer
wonder how this hits Gerald's kiss ass faithful lap dog and shoe shine boy Mr Redsputter the shill - eh Redsie...?
can you even count to 3-billion - I didn't think so lolzzz
its obvious his reputations like yours is permanently shot - AMBS, VERB, TOMDF, etc.
hey by the way - you guys are adorable together....
heard Redise said he called the SEC on me - wonderful - now he's been made by the Fed
that is of course if he didn't use any one of his million fake aliases, burner phones or phony IP addy's
what a proverbial dead beat...
just saying - for a friend of course...!
MOO dorkus maximus
will be interesting to see who....
Frank had the ability to take MONI and BitGift places
1. crystal clean SS
2. no debt on books
3. no dilution - none - nada - nill - zilch
4. current Pink filing status
5. timely security filings
6. minute OH, GnA & OE's
7. reduced millions of shares w/no cost to SH’s
8. low consistent float - moves on thin air
9. unencumbered by “dead weight” liabilities on the books
10. unencumbered by “dead weight” liabilities on the books
11. acquisition target as a wholly owned sub thru non-dilutive measures
12. new acquisition target generating millions in revenue’s with “audited” financials
13. high probability of further share reductions
14. BitGift trademarked & spun-off
COVID global pandemic, economic peril, an untimely stroke, FTX's billion dollar crypto debacle & collapse - all didn't help things
just keeping it real...!
BAF MONI
got the sense Scott Harmolin will smoke the shorts
including all these low-life, pesky, pathetic and ignorant naysayers
would not all be surprised when he arrives with +$50-Mil. cash flow positive revenue in tow (potentially more)
and performs a share reduction right outta the starting gate
with uplisting on the horizon - and a CUSIP change that would flush any naked shorts down the septic tank shit-hole
and puts the new ticker on solid grounds at the same time
this guy has the Ways & Means to make a significant market splash
and I for one suspect he intuitively knows this to be rare opportunity to do just that.....!
AJMHO
Mr Redspudder
big man - more like little twirp
Moo joke
oh Mr Redspudder
did I touch a sensative nerve…?
hows that TOMDF sp looking these daze…?
you and the Back Office Promo Boyzzz not gettin it done - eh?
printing $0.0005 while Gerry serial dilutes on toxic death spiral convertibles…?
you’re fired pal - lolzzz
SMH - nuff said
MOO pathetic
more "Financial Engineering" of course
from the Stanford University football player himself...
but hey - no worries ...
lookie here, we got Greg working on DC and 3CL is next up
lots & lots & lots coming folks...!
Sham-Wow - you be rockin now Gerry ...!
get a life…
BAF MONI …!
Relative Strength Index (RSI)
she’s setting-up for the next leg up
can you smell it …?
BAF MONI
Saaaaweeeeet…..!!!
BAF MONI
If they do…
it won’t be toxic death spiral dilutive financing…
that evicerates all shareholders like your love interest Gerald does to his TOMDF beleaguered shareholders
dumptin’s up w/Ibio Buchweat
nuff said …!
MOO shill n tout
MONI trades on thin air
mo mo mo MONI…!
Ibio on the prowl….
TOMDF - not so much…
nuff said…!
MOO dunce
here fishy fishy 🐠
NVOS champs taking their winnings over to MONI
ain’t seen nothin yet Mr Redspudder
BAF MONI…!
nuff said
DB's pick NVOS on an absolute tear...
MONI next - nuff said
BAF MONI...!
Frank this is getting stale…
need some juice partner
BAF MONI
maybe Redsputters VERB will eventually repair his shot reputation
just like his TOMDF and AMBS pumps - prolly not though …!
a pumper is nothing more than a shill tout and tool
what a pathetic Gerald loving, arse licking lap dawg Redspudder is
worthless POS sad but true
MOO dung
June 29, 2023 buyers like Vanguard, Blackrock, State St. were showing up...
new CEO bought in August 27, 2023 along with CTO
iBio Forges Research Collaboration with the National Institutes of Health
https://www.discoveryontarget.com/ai-drug-discovery-part1
AI/ML-Enabled Drug Discovery – Part 1
AI/ML for Identifying Novel Targets and Pathways
SEPTEMBER 26 - 27, 2023 EDT
https://www.discoveryontarget.com/ai-drug-discovery-part1
shorts playing jiggy bigley, bottom looks to be about in...
EOM
right here clownie
you still pumpin that crap VERB, AMBS and TOMDF...?
iBio Forges Research Collaboration with the National Institutes of Health
June 12, 2023 16:15 ET
– NIH to evaluate iBio’s patented AI-driven epitope steering platform for Lassa fever vaccine development –
BRYAN, Texas and SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the Company has entered into a research collaboration with the National Institute of Allergy and Infectious Diseases (“NIAID”), a component of the National Institutes of Health (“NIH”), to investigate the potential of iBio’s patented AI-driven epitope steering platform for the development of a vaccine for Lassa fever, a sometimes fatal viral disease endemic to parts of West Africa.1 There is currently no vaccine available to prevent Lassa fever.
Based on the viral epitopes identified by researchers at NIAID’s Vaccine Research Center (“VRC”), iBio will work with the VRC to determine if using iBio’s platform to steer immunity toward these epitopes offers advantages over other vaccine development approaches. Should the collaboration be successful, researchers at the VRC may assess promising candidates in both in vitro and in vivo studies, and potentially advance a lead candidate to a Phase 1 clinical trial.
“This collaboration with the NIH represents a potential new application for, and validation of our patented AI discovery platform,” said Martin Brenner, DVM, Ph.D., iBio’s Interim Chief Executive Officer and Chief Scientific Officer. “While we remain focused on deploying our core technology to internally discover and develop therapeutic candidates for oncology, we believe our differentiated vaccine development capabilities could also make us an ideal partner for RNA- and peptide-based vaccine developers.”
Epitopes represent specific regions within viral proteins that can be recognized by the human immune system. They encompass an amino acid sequence that folds into a distinct three-dimensional shape within the full-length viral protein. However, when epitope sequences are isolated, there is a risk of incorrect folding, which can obscure critical epitope regions or alter antibody binding sites. This scenario potentially undermines the generation of an effective antibody response.2
iBio's patented AI powered epitope steering platform offers a potential solution by generating engineered epitopes. These epitopes not only possess the correct amino acid sequence, but also faithfully reproduce the precise structural characteristics of the original epitope. Consequently, the immune system may gain an enhanced ability to target the original viral protein, bolstering its defensive response.
By providing engineered epitopes with the accurate sequence and structure, artificial intelligence opens up the possibility of targeting otherwise inaccessible epitopes, which could facilitate the development of vaccines against previously intractable diseases or could contribute to the creation of vaccines with improved protective capabilities.
“This approach is particularly exciting because of the potential to incorporate multiple, easily producible engineered epitopes within a single vaccine, which holds promise for a multi-faceted attack on viruses,” Dr. Brenner said. “This could lead to enhanced protection or the ability to confer immunity against diverse viral variants.”
References
Lassa Fever | CDC. https://www.cdc.gov/vhf/lassa/index.html (2022).
Malonis, R. J., Lai, J. R. & Vergnolle, O. Peptide-Based Vaccines: Current Progress and Future Challenges. Chem. Rev. 120, 3210–3229 (2020).
About iBio, Inc.
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.
no dilution - MONI moves on thin air…
BAF MONI…!